1.Minimally Invasive Treatment for Acromioclavicular Joint Dislocation
Hanyu LU ; Hongquan JI ; Fang ZHOU
Chinese Journal of Minimally Invasive Surgery 2016;16(10):939-941
[Summary] Acute acromioclavicular joint dislocation is a common injury of the shoulder .Its surgical treatment is various .In recent years , with the promotion of arthroscopic techniques , arthroscopic treatment has gradually become a hot spot in the field of minimally invasive treatment for acute acromioclavicular joint dislocation .There are various types of internal fixation .The overall treatment effect is satisfactory .In this review we summarized minimally invasive treatment for acromioclavicular joint dislocation .
2.The influence of montelukast on inflammatory factors and clinical symptoms in children with mild asthma
Chinese Journal of Primary Medicine and Pharmacy 2013;20(13):1996-1998
Objective To investigate the application effect of montelukast in children with mild asthma.Methods 120 patients with mild asthma were randomly divided into the treatment group and the control group,the control group was given conventional therapy,the treatment group was treated with montelukast on the basis of the control group.Two groups were treated for 4 weeks as a course.Results The total effective rate of treatment group was 91.7%,which was significantly higher than 73.3% in the control group (x2 =3.89,P <0.05).The daytime and nighttime asthma score in the treatment group were (0.13 ± 0.05)points,(0.12 ± 0.04)points,which were significantly lower than (1.13 ± 0.21) points,(0.43 ± 0.23) points in the control group.The symptom-free days was (17.43 ± 2.87) d,which was significantly longer than (9.34 ± 1.57) d in the control group(t =2.32,1.97,5.75,all P < 0.05).IL-6,TNF-α,IgE in the treatment group after the treatment were (140.5 ± 6.4) ng/L,(40.1 ± 4.9) IU/ml,(105.6 ± 8.8) IU/ml,which were significantly lower than (189.3 ± 9.7) ng/L,(78.6 ± 7.5) 1U/ml,(155.4 ±10.5) IU/ml in the control group (t =11.97,8.75,13.56,all P < 0.05).The incidence rate of adverse reaction in the treatment group was 13.3% and 10% in the control group,there was no significant ditterence(x2 =1.32,P >0.05).Conclusion Montelukast can significantly improve the inflammatory state in children with mild asthma,relieve clinical symptoms,improve the therapeutic effect,and has less adverse reactions.
3.Influence of intensity-modulated radiotherapy on tumor regression in nasopharyngeal carcinoma
Fei HAN ; Weiwei XIAO ; Hanyu WANG ; Ying HUANG ; Meiling DENG ; Chong ZHAO ; Taixiang LU
Chinese Journal of Radiological Medicine and Protection 2012;32(2):204-206
Objective To retrospectively analyze the influence of intensity-modulated radiotherapy (IMRT) on tumor regression in primary nasopharyngeal carcinoma (NPC).Methods 272 patients with NPC received radical radiotherapy alone,196 by IMRT with a total treatment time of 6 weeks,and 76 by bilateral field conventional radiotherapy (CRT) with the total treatment timc of 7 weeks.Results By the end of radiotherapy,the primary tumor and neck lymph node residual rates of the IMRT group were 36.7% and 44.2%,respectively,both significantly higher than those of the GRT group (21.1% and 26.6%,x2 =6.15,3.99,P < 0.05).Three months after the radiotherapy,residual lesions were observed at the nasopharynx or neck lymph nodes in 12 of the IMRT group,with a residual rate of 6.1%,not significantly different from that of the CRT group (9.2%,7/76).The 12 residual lesions of the IMRT group all vanished completely 4 -9 months after the radiotherapy.Conclusions There is an obvious difference in regressive mode between IMRT and CRT technique in NPC treatment.At the end of IMRT,the tumor residual rate is slightly increased.However,the delivered dose of gross tumor volume (GTV) is sufficient,and the boost dose should not be delivered indiscreetly.
4.Tendency of quality of life in patients with nasopharyngeal carcinoma treated with conventional radiotherapy
Weiwei XIAO ; Taixiang LU ; Jiaxin LI ; Qing LIU ; Chong ZHAO ; Fei HAN ; Hanyu WANG
Chinese Journal of Radiation Oncology 2010;19(2):87-91
Objective To investigate the tendency of quality of life in patients with nasopharyngeal carcinoma (NPC) treated with conventional radiotherapy. Methods Quality of life in NPC patients was assessed using FACT-H&N and NPC-QOL Patients were divided into nine groups according to the treatment period :before treatment group, 0 -20 Gy group, 20 -50 Gy group, > 50 Gy group, 0 -6 months after treatment group, 6 - 12 mouths group, 1 -2 years group, 2 -3 years group and 3 -5 years group. Scores of FACT-H&N and NPC-QOL were compared between the either two groups. Results 450 NPC patients were assessed. The total score of FACT-H&N decreased during the treatment and then increased six months after the treatment. The tendencies of physical and functional well-being were similar. The social/family and emotional well-being did not change significantly along with the treatment but the scores of head and neck well-being and NPC-QOL decreased obviously. Xerotomia was aggravated from the initiation of treatment and became the most severe at 6 - 12 months after treatment. 50% - 60% of the patients with disease-free reported severe xerotomia at 3 -5 years after radiotherapy. Incidence of severe trismus increased up to 14% at 3 -5 years after treatment. Conclusions Quality of life of NPC patients with conventional radiotherapy deteriorates during the treatment period, but recovers to the normal level six months after the treatment. Xerotomia and trismus can affect the quality of life of NPC patients.
5. Clinical analysis of sinonasal chondrosarcoma in 47 cases
Wanpeng LI ; Hanyu LU ; Huan WANG ; Huankang ZHANG ; Quan LIU ; Xicai SUN ; Li HU ; Dehui WANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2020;55(1):14-20
Objective:
To discuss the treatment, pathological subtypes and recurrence of sinonasal chondrosarcoma, and to identify the prognostic factors.
Methods:
Between January 1994 and May 2018, 47 patients with sinonasal chondrosarcoma who were treated in Eye, Ear, Nose and Throat Hospital, Shanghai Medwal College, Fudan University were retrospectively reviewed, including 19 males and 28 females, aging from 7 months to 71 years old, with a median age of 38 years old. The clinical symptoms, location of tumor, surgical method, pathological subtype, recurrence and prognosis were collected and analyzed. Kaplan-Meier method was used to calculate the disease-specific survival rate, disease-free survival rate and draw survival curve. Log Rank was used to analyze the prognostic factors. Cox regression was used for multivariate analysis.
Results:
Except for one patient who gave up treatment after tumor biopsy, other 46 patients underwent radical resection, including 31 cases of endoscopic resection and 15 cases of extranasal approach resection. Thirty-nine patients were diagnosed as conventional intramedullary chondrosarcoma with pathological grade Ⅰ of 24 cases and grade Ⅱ of 15 cases. Six cases were diagnosed as mesenchymal chondrosarcoma while 2 cases were diagnosed as myxoid chondrosarcoma. During an average follow-up period of 56.1 months (17-156 months), 23 patients had recurrence (54.8%, 23/42), among whom 9 patients had re-operations and 5 patients died. Thirty-seven patients survived, including 25 patients survived without tumors. In addition, 5 patients were lost to follow-up, including the patient who gave up treatment after tumor biopsy. Five-year overall survival rate and disease-free survival rate was 84.7% and 34.3%, respectively. Multivariate analysis showed that invasion of skull base was an independent risk factor affecting disease-free survival rate (95% confidence interval: 1.089-5.825,
6.Hepatic retinaldehyde deficiency is involved in diabetes deterioration by enhancing PCK1- and G6PC-mediated gluconeogenesis.
Hanyu YANG ; Mengxiang SU ; Ming LIU ; Yun SHENG ; Liang ZHU ; Lu YANG ; Ruijing MU ; Jianjun ZOU ; Xiaodong LIU ; Li LIU
Acta Pharmaceutica Sinica B 2023;13(9):3728-3743
Type 2 diabetes (T2D) is often accompanied with an induction of retinaldehyde dehydrogenase 1 (RALDH1 or ALDH1A1) expression and a consequent decrease in hepatic retinaldehyde (Rald) levels. However, the role of hepatic Rald deficiency in T2D progression remains unclear. In this study, we demonstrated that reversing T2D-mediated hepatic Rald deficiency by Rald or citral treatments, or liver-specific Raldh1 silencing substantially lowered fasting glycemia levels, inhibited hepatic glucogenesis, and downregulated phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) expression in diabetic db/db mice. Fasting glycemia and Pck1/G6pc mRNA expression levels were strongly negatively correlated with hepatic Rald levels, indicating the involvement of hepatic Rald depletion in T2D deterioration. A similar result that liver-specific Raldh1 silencing improved glucose metabolism was also observed in high-fat diet-fed mice. In primary human hepatocytes and oleic acid-treated HepG2 cells, Rald or Rald + RALDH1 silencing resulted in decreased glucose production and downregulated PCK1/G6PC mRNA and protein expression. Mechanistically, Rald downregulated direct repeat 1-mediated PCK1 and G6PC expression by antagonizing retinoid X receptor α, as confirmed by luciferase reporter assays and molecular docking. These results highlight the link between hepatic Rald deficiency, glucose dyshomeostasis, and the progression of T2D, whilst also suggesting RALDH1 as a potential therapeutic target for T2D.
7.Repurposing vitamin D for treatment of human malignancies targeting tumor microenvironment.
Xu WU ; Wei HU ; Lan LU ; Yueshui ZHAO ; Yejiang ZHOU ; Zhangang XIAO ; Lin ZHANG ; Hanyu ZHANG ; Xiaobing LI ; Wanping LI ; Shengpeng WANG ; Chi Hin CHO ; Jing SHEN ; Mingxing LI
Acta Pharmaceutica Sinica B 2019;9(2):203-219
Tumor cells along with a small proportion of cancer stem cells exist in a stromal microenvironment consisting of vasculature, cancer-associated fibroblasts, immune cells and extracellular components. Recent epidemiological and clinical studies strongly support that vitamin D supplementation is associated with reduced cancer risk and favorable prognosis. Experimental results suggest that vitamin D not only suppresses cancer cells, but also regulates tumor microenvironment to facilitate tumor repression. In this review, we have outlined the current knowledge on epidemiological studies and clinical trials of vitamin D. Notably, we summarized and discussed the anticancer action of vitamin D in cancer cells, cancer stem cells and stroma cells in tumor microenvironment, providing a better understanding of the role of vitamin D in cancer. We presently re-propose vitamin D to be a novel and economical anticancer agent.